South Korea

Reimbursed Care Access

South Korea maintains a restrictive legal regime for classical psychedelics: most serotonergic/hallucinogenic compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca/DMT‑containing plants, mescaline, 2C‑X) are controlled under the national Narcotics Control Act and have no authorized medical use outside approved research. Esketamine is an exception — it received domestic marketing authorization and is available through regulated medical settings, while racemic/other ketamine formulations remain legal for approved medical uses (anesthesia, analgesia) and are used off‑label in private psychiatric practice for depression but generally without routine public insurance reimbursement for psychiatric indications.